Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

VIENNA, AUSTRIA — Thrombi were sometimes found on two left-atrial-appendage (LAA) occluder devices in the weeks following implantation in two large registry studies of patients with atrial ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder was approved nearly two years ago. Here are five things to know about the minimally invasive device: 1. The product closes the left atrial ...

W.L. Gore & Associates announced today that it agreed to acquire left atrial appendage occlusion (LAAO) device maker ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. BOSTON — At 3 years, the Amplatzer Amulet device ...

BOSTON, MA—For patients with atrial fibrillation who are undergoing left atrial appendage occlusion (LAAO), the Amplatzer Amulet (Abbott) and the first-generation Watchman 2.5 (Boston Scientific) ...

New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in minimizing blood leakage around the valve implant ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...